<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 18 Mar 2021 11:19:53 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>国内首个：嘉和生物CD3/CD20双抗申报临床</title><link>https://mp.weixin.qq.com/s/ia6OjJd3ygb5IpNnfkNVHg</link><description></description><content:encoded><![CDATA[国内首个：嘉和生物CD3/CD20双抗申报临床]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>CCR8 目前尚无一例进入临床的热门靶点？</title><link>https://mp.weixin.qq.com/s/2Ri9UqqOvWYkkS2mxKkh7Q</link><description></description><content:encoded><![CDATA[CCR8 目前尚无一例进入临床的热门靶点？]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>恒瑞医药研发CD38抗体、IL-4R抗体</title><link>https://mp.weixin.qq.com/s/zrQIA5Fw321glRW9LtLd4g</link><description></description><content:encoded><![CDATA[恒瑞医药研发CD38抗体、IL-4R抗体]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>商业化前奏：突飞猛进的中国抗体药产能</title><link>https://mp.weixin.qq.com/s/81_1fV7vkIEC4GQrEazOAw</link><description></description><content:encoded><![CDATA[商业化前奏：突飞猛进的中国抗体药产能]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>ACC：抗体细胞偶联药物</title><link>https://mp.weixin.qq.com/s/IlRitHXtUfyRRXpUjZLlPQ</link><description></description><content:encoded><![CDATA[ACC：抗体细胞偶联药物]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>辉瑞小分子GLP-1R激动剂国内获批临床</title><link>https://mp.weixin.qq.com/s/f0UeoAI1p6CrvI7J6uCzGA</link><description></description><content:encoded><![CDATA[辉瑞小分子GLP-1R激动剂国内获批临床]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>首药控股科创板IPO，拟募资20亿元</title><link>https://mp.weixin.qq.com/s/Y0pAdiTHnQmdf9f4m9pHSQ</link><description></description><content:encoded><![CDATA[首药控股科创板IPO，拟募资20亿元]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>IL-7与肿瘤免疫治疗</title><link>https://mp.weixin.qq.com/s/XU5qYN-EsX-O1cD2gIoA5Q</link><description></description><content:encoded><![CDATA[IL-7与肿瘤免疫治疗]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>复宏汉霖CD73抗体启动临床，国内第3家</title><link>https://mp.weixin.qq.com/s/cZ30OPbYM489eKHNGcTpqA</link><description></description><content:encoded><![CDATA[复宏汉霖CD73抗体启动临床，国内第3家]]></content:encoded><pubDate>Tue, 16 Mar 2021 08:23:55 +0800</pubDate></item><item><title>赛诺菲/Translate Bio新冠mRNA疫苗启动临床研究</title><link>https://mp.weixin.qq.com/s/S-pAsEbwHnuzOnD7zyhAkA</link><description></description><content:encoded><![CDATA[赛诺菲/Translate Bio新冠mRNA疫苗启动临床研究]]></content:encoded><pubDate>Tue, 16 Mar 2021 08:23:55 +0800</pubDate></item><item><title>普米斯生物技术全梳理</title><link>https://mp.weixin.qq.com/s/9ah89hSWmTUVURNa23aARw</link><description></description><content:encoded><![CDATA[普米斯生物技术全梳理]]></content:encoded><pubDate>Mon, 15 Mar 2021 11:06:38 +0800</pubDate></item><item><title>礼来Aβ抗体二期临床达到主要终点，却错失所有次要终点</title><link>https://mp.weixin.qq.com/s/o9W8mPx8MiABhmYd_UXrHQ</link><description></description><content:encoded><![CDATA[礼来Aβ抗体二期临床达到主要终点，却错失所有次要终点]]></content:encoded><pubDate>Sun, 14 Mar 2021 06:56:24 +0800</pubDate></item><item><title>百利药业四抗启动实体瘤临床研究</title><link>https://mp.weixin.qq.com/s/tOFRR4U-RwEJhMlMPvJoVQ</link><description></description><content:encoded><![CDATA[百利药业四抗启动实体瘤临床研究]]></content:encoded><pubDate>Sat, 13 Mar 2021 07:40:22 +0800</pubDate></item><item><title>诺和诺德每周一次胰岛素Icodec启动德谷胰岛素对照三期临床</title><link>https://mp.weixin.qq.com/s/ITNGfUYPJ_E4P-fzXN11hQ</link><description></description><content:encoded><![CDATA[诺和诺德每周一次胰岛素Icodec启动德谷胰岛素对照三期临床]]></content:encoded><pubDate>Sat, 13 Mar 2021 07:40:22 +0800</pubDate></item><item><title>进击的疫苗新秀，落寞的巨头</title><link>https://mp.weixin.qq.com/s/qE0S9lpTQZx7771G17djFA</link><description></description><content:encoded><![CDATA[进击的疫苗新秀，落寞的巨头]]></content:encoded><pubDate>Fri, 12 Mar 2021 08:26:00 +0800</pubDate></item><item><title>康诺亚IL-4R呼吸适应症授权石药，CM326哮喘获批临床</title><link>https://mp.weixin.qq.com/s/_I2FSLdXQrfeJwuUcp31vg</link><description></description><content:encoded><![CDATA[康诺亚IL-4R呼吸适应症授权石药，CM326哮喘获批临床]]></content:encoded><pubDate>Fri, 12 Mar 2021 08:26:00 +0800</pubDate></item><item><title>媲美mRNA疫苗：Novavax三聚体蛋白疫苗有效率96.4%</title><link>https://mp.weixin.qq.com/s/rHm3w8vd1myNjk7ntd1jGA</link><description></description><content:encoded><![CDATA[媲美mRNA疫苗：Novavax三聚体蛋白疫苗有效率96.4%]]></content:encoded><pubDate>Fri, 12 Mar 2021 08:26:00 +0800</pubDate></item><item><title>国内首个：恒瑞医药Aβ抗体获批临床，治疗阿尔茨海默症</title><link>https://mp.weixin.qq.com/s/Ohd7Ua5I8zABTZd7dTKtRw</link><description></description><content:encoded><![CDATA[国内首个：恒瑞医药Aβ抗体获批临床，治疗阿尔茨海默症]]></content:encoded><pubDate>Thu, 11 Mar 2021 08:58:25 +0800</pubDate></item><item><title>天境生物引进穿膜抗体技术：Alphabody</title><link>https://mp.weixin.qq.com/s/4bDBOvXF2AZnZr_C_7jeiw</link><description></description><content:encoded><![CDATA[天境生物引进穿膜抗体技术：Alphabody]]></content:encoded><pubDate>Thu, 11 Mar 2021 08:58:25 +0800</pubDate></item><item><title>CD3双抗靶向TCR，治疗T细胞淋巴瘤</title><link>https://mp.weixin.qq.com/s/_-Qw46mEWvmUUAECRGiqIg</link><description></description><content:encoded><![CDATA[CD3双抗靶向TCR，治疗T细胞淋巴瘤]]></content:encoded><pubDate>Thu, 11 Mar 2021 08:58:25 +0800</pubDate></item></channel></rss>